PYZCHIVA

GrowthmAb

ustekinumab-ttwe

Samsung Bioepis
BLASUBCUTANEOUSINJECTABLE
Approved
Jun 2024
Lifecycle
Growth
Competitive Pressure
30/100

Mechanism of Action

Interleukin-12 Antagonists

Pharmacologic Class:

Interleukin-12 Antagonist

Company
Samsung Bioepis
Samsung Bioepis
Korea - Incheon
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers